Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography

Annals of Neurology

Volumn 40, Issue 6, 1996, Pages 885-892

  Gilman, Sid ^a,c   Frey, Kirk A ^a   Koeppe, Robert A ^a   Junck, Larry ^a   Little, Roderick ^b   Vander Borght, Thierry M ^a   Lohman, Mary ^a   Martorello, Susan ^a   Lee, Lihsueh C ^a   Jewett, Douglas M ^a   Kilbourn, Michael R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BACLOFEN; CARBIDOPA PLUS LEVODOPA; CARBON 11; CLONAZEPAM; DIHYDROTETRABENAZINE; FLUOXETINE; LEVODOPA; MONOAMINE; SELEGILINE;

ADULT; AGED; AMINE TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DISTRIBUTION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONOAMINERGIC NERVE; NIGRONEOSTRIATAL SYSTEM; OLIVOPONTOCEREBELLAR ATROPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SHY DRAGER SYNDROME;

ADULT; AGED; AUTONOMIC NERVOUS SYSTEM DISEASES; BASAL GANGLIA DISEASES; BIOLOGICAL TRANSPORT; CEREBELLAR DISEASES; CORPUS STRIATUM; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEUROPEPTIDES; OLIVOPONTOCEREBELLAR ATROPHIES; PRESYNAPTIC TERMINALS; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 8044237122     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400610     Document Type: Article

References (50)

1. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52(special suppl):78-89
2. Quinn N. Multiple system atrophy. In: Marsden CD. Fahn S, eds. Movement disorders 3. London: Butterworths, 1994:262-281
3. Polinsky RJ. Multiple system atrophy. Clinical aspects, pathophysiology and treatment. Neurol Clin 1984;2:487-498
4. Wenning GK, Ben Shlomo Y, Magalhães M, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835-845
5. Colosimo C, Albanese A, Hughes AJ, et al. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995;52:294-298
6. Wenning GK, Ben Shlomo Y, Maglahães M, et al. Clinico-pathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166
7. Oppenheimer DR, Esiri MM. Diseases of the basal ganglia, cerebellum and motor neurons. In: Hume Adams J, Duchen LW, eds. Greenfield's neuropathology. 5th ed. London: Edward Arnold, 1992:988-1045
8. Kume A, Takahashi A, Hashizume Y, Asai J. A histometrical and comparative study on Purkinje cell loss and olivary nucleus cell loss in multiple system atrophy. J Neurol Sci 1991;101: 178-186
9. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinico-pathological study. Brain 1990;113:1823-1842
10. Gibb WRG. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgraduate Med J 1988;64:345-351
11. Borit A, Rubinstein LJ, Urich H. The Striatonigral degenerations: putaminal pigments and nosology. Brain 1975;98:101-112
12. Takei Y, Mirra SS. Striatonigral degeneration: a form of multiple system atrophy with clinical parkinsonism. In: Zimmerman HM, ed. Progress in neuropathology. New York: Grune & Stratton, 1973:217-251
13. Cohen J, Low P, Fealey R, et al. Somatic and autonomie function in progressive autonomie failure and multiple system atrophy. Ann Neurol 1987;22:692-699
14. Spokes EGS, Bannister R, Oppenheimer DR. Multiple system atrophy with autonomie failure. J Neurol Sci 1979;43:59-82
15. Sung JH, Mastri AR, Segal E. Pathology of Shy-Drager syndrome. J Neuropathol Exp Neurol 1979;38:353-368
16. Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system associated with autonomie failure. Brain 1972; 95:457-474
17. Papp MI, Khan JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (Striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79-100
18. Nakazato Y, Yamazaki H, Hirato J, et al. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. J Neuropathol Exp Neurol 1990;49:521-530
19. Kato S, Nakamura H, Hirano A, et al. Argyrophilic ubiquinated cytoplasmic inclusions in Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol (Berl) 1991;82:488-493
20. Mochizuki A, Mizusawa H, Ohkoshi N, et al. Argentophilic intracytoplasmic inclusions in multiple system atrophy. J Neurol 1992;239:311-316
21. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117:235-243
22. Kato S, Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol (Berl) 1990;79:584-594
23. Papp MI, Lantos PL. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 1992;107:172-182
24. Lantos PL, Papp MI. Cellular pathology of multiple system atrophy: a review. J Neurol Neurosurg Psychiatry 1994;57: 129-133
25. Eadie MJ. Olivo-ponto-cerebellar atrophy (Dejerine-Thomas type). In: PJ Vinken, GW Bruyn, eds. Handbook of clinical neurology. Amsterdam: North-Holland, 1975:415-431
26. Eadie MJ. Olivo-ponto-cerebellar atrophy (Menzel type). In: PJ Vinken, GW Bruyn, eds. Handbook of clinical neurology. Amsterdam: North-Holland, 1975:433-449
27. Berciano J. Olivopontocerebellar atrophy. A review of 117 cases. J Neurol Sci 1982;53:253-272
28. Duvoisin RC. An apology and an introduction to the olivopontocerebellar atrophies. In: Duvoisin RC, Plaitakis A, eds. The olivopontocerebellar atrophies. New York: Raven, 1984: 5-12
29. Harding A. 'Idiopathic' late onset cerebellar ataxia. In: Harding A, ed. The hereditary ataxias. Boston: Butterworths, 1984: 166-173
30. Koeppen AH, Baron KD. The neuropathology of olivopontocerebellar atrophy. In: Duvoisin RC, Plaitakis A, eds. The olivopontocerebellar atrophies. New York: Raven, 1984:13-38
31. Koeppen AH. The Purkinje cell and its afferents in human hereditary ataxia. J Neuropathol Exp Neurol 1991;50:505-514
32. Ferrer I, Genís D, Dávalos A, et al. The Purkinje cell in olivopontocerebellar atrophy. A Golgi and immunocytochemical study. Neuropathol Appl Neurobiol 1994;20:38-46
33. Kilbourn MR, Lee LC, Vander Borght TM, et al. Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995;278:249-252
34. Kilbourn MR, Frey KA, Koeppe RA, et al. In vivo imaging of monoaminergic nerve terminal losses using ligands for the synaptic vesicle monoamine transporter. Q J Nucl Med 1995;39: 32-34
35. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884
36. 11C]dihydrotetrabenazine and PET. J Cereb Blood Flow Metab 1995;15(suppl 1):S752
37. McLeod JG, Tuck RR. Disorders of the autonomic nervous system: part 2. Investigation and treatment. Ann Neurol 1987; 21:519-529
38. Gilman S, Markel DS, Koeppe RA, et al. Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann Neurol 1988;24: 223-230
39. Kluin KJ, Gilman S, Markel DS, et al. Speech disorders in olivopontocerebellar atrophy correlate with positron emission tomography findings. Ann Neurol 1988;23:547-554
40. Koeppe RA, Frey KA, Vander Borght TM, et al. Kinetic evaluation of [C-11]dihydrotetrabenazine (DTBZ) by dynamic PET: a marker for the vesicular monoamine transporter. J Cereb Blood Flow Metab 1995;15:S651
41. De Volder AG, Francart J, Laterre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989;26:239-247
42. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993;33:518-527
43. Gilman S, Koeppe RA, Junck L, et al. Patterns of cerebral glucose metabolism detected with PET differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994;36:166-175
44. 18F]fluorodeoxyglucose in multiple system atrophy and pure autonomie failure. Clin Autonom Res 1991; 1:27-36
45. Perani D, Bressi S, Testa D, et al. Clinical/metabolic correlations in multiple system atrophy. Arch Neurol 1995;52:179-185
46. Bhatt MH, Snow BJ, Martin WRW, et al. Positron emission tomography in Shy-Drager syndrome. Ann Neurol 1990;28: 101-103
47. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomie dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539-1552
48. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57:278-284
49. Rinne JO, Burn DJ, Mathias CJ, et al. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol 1995;37:568-573
50. Kish SJ, Robitaille Y, El-Awar M, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 1992;42:1573-1577